In particular, the molecular pathway of the TCA cycle, its downstream pathways, and their possible alteration in patients with GBM have been examined in both IDH-1 wild-type and mutant forms and compared to the mechanisms found in healthy cells. The gene discussed is IDH1; the disease is glioblastoma.